Table 1.

Summary of dose personalization and estimated effect on LRC.

	$\mathbf{Clinical} \mathit{D}$	${\mathit{D}}_{\mathbf{DARD}}$	${\mathit{D}}_{\mathbf{DARD}}^{*}$
Mean Escalation (Gy)	0	38.9	12.4
Mean De-Escalation (Gy)	0	32.0	10.7
LRC Rate	84.6%	100%	94.9% 1

¹ Estimated based on number of escalated patients for whom $D_{\mathrm{DARD}}^{*}=D_{\mathrm{DARD}}$